Shattuck Labs, Inc. Debt Securities, Available-for-sale
Shattuck Labs, Inc. (STTK) had Debt Securities, Available-for-sale of $44.66 million as of 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2024-02-29
- 2023-12-31: Debt Securities, Available-for-sale $44.66M.
- 2023-09-30: Debt Securities, Available-for-sale $60.44M.
- 2023-06-30: Debt Securities, Available-for-sale $45.28M.
- 2023-03-31: Debt Securities, Available-for-sale $69.45M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2023-12-31 | $44.66M 10-K · filed 2024-02-29 |
| 2023-09-30 | $60.44M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $45.28M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $69.45M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $113.90M 10-K · filed 2024-02-29 |
| 2021-12-31 | $176.54M 10-K · filed 2023-02-23 |
| 2021-09-30 | $205.12M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $218.30M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $236.44M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $177.55M 10-K · filed 2022-03-15 |
| 2020-09-30 | $6.34M 10-Q · filed 2020-11-13 |
| 2019-12-31 | $32.07M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |